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Graphical abstract
Abstract Systemic toxicity and insufﬁcient drug accumulation at the tumour site aremain barriers in chemotherapy.
Thermosensitive liposomes (TSL) combined with high intensity focused ultrasound (HIFU) has emerged
as a potential solution to overcome these barriers through targeted drug delivery and localised release.
Owing to the multiple physical and biochemical processes involved in this combination therapy,
mathematical modelling becomes an indispensable tool for detailed analysis of the transport processes
and prediction of tumour drug uptake. To this end, a multiphysics model has been developed to simulate
the transport of chemotherapy drugs delivered through a combined HIFU–TSL system. All key delivery
processes are considered in the model; these include interstitial ﬂuid ﬂow, HIFU acoustics, bioheat
transfer, drug release and transport, as well as tumour drug uptake. The capability of the model is
demonstrated through its application to a 2-D prostate tumour model reconstructed from magnetic
resonance images. Our results not only demonstrate the feasibility of the model to simulate this combi-
nation therapy, but also conﬁrm the advantage of HIFU–TSL drug delivery system with enhancement of
drug accumulation in tumour regions and reduction of drug availability in normal tissue. Thismultiphysics
modelling framework can serve as a useful tool to assist in the design of HIFU–TSL drug delivery systems
and treatment regimen for improved anticancer efﬁcacy.
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INTRODUCTION
Numerous anticancer drugs have been developed with
signiﬁcant cytotoxicity observed in preclinical studies,
but their clinical applications are limited for various
reasons. Among these poor treatment efﬁcacy and sys-
temic toxicity are the main obstacles for effective
chemotherapy in patients. This is largely attributed to
insufﬁcient drug penetration from microvasculature
into tumour interior (Jain 1987a), resulting in inade-
quate drug accumulation for effective tumour cell kill-
ing. On the other hand, undesirable drug deposition in
normal tissue may damage healthy cells so as to cause
various side effects.
Thermosensitive liposome (TSL) combined with high
intensity focused ultrasound (HIFU) offers a promising
drug delivery system to overcome the limitations of
conventional chemotherapy through actively targeted
and triggered release of drugs at the tumour site. With
this delivery system, drug-loaded TSL are intravenously
administrated and then circulate with bloodstream to
reach the tumour site. For well-designed TSL that are
stable in blood, encapsulated drugs cannot be released
at normal physiological temperature, and mild hyper-
thermia is required to trigger the release of the encap-
sulated contents (Gaber et al. 1995; Lindner et al. 2004;
Tagami et al. 2011). Localised heating can be achieved
by HIFU, which is favoured for its non-invasive nature
and accuracy in clinical thermal therapy (Hynynen
2011). The safety and feasibility of the combined
HIFU–TSL system have been reported in a very recent
clinical trial, demonstrating enhanced intratumoural
drug delivery for targeted treatment of liver tumours
(Lyon et al. 2018). However, there is still a lack of
understanding on the drug transport mechanism and
tumour drug uptake in response to temperature varia-
tion upon HIFU heating.
Given the multiple steps involved in heat transfer and
drug transport and the complex interplays among
tumour, TSL and anticancer drugs, mathematical mod-
elling plays an increasingly important role in gaining a
deep understanding of drug delivery systems and pre-
dicting their treatment efﬁcacy. Early mathematical
models (Baxter and Jain 1989, 1990, 1991) were
developed to study the transport of interstitial ﬂuid and
macromolecules in solid tumour. These were subse-
quently extended to multiple scales for examining the
effects of different factors on drug delivery (Eikenberry
2009; El-Kareh and Secomb 2000; Goh et al. 2001; Liu
et al. 2013; Luu and Uchizono 2005; Teo et al. 2005;
Zhao et al. 2007). Results based on a 1-D drug transport
model demonstrated the importance of blood
temperature in determining the overall delivery out-
come using TSL (El-Kareh and Secomb 2003). The
performance of TSL was further compared to conven-
tional chemotherapy and stealth liposomes under dif-
ferent conditions (Gasselhuber et al. 2012a), whilst a
systematic parametric study was performed to identify
the most inﬂuential factors in determining the peak
intracellular concentration using a TSL–HIFU system
(Liu and Xu 2015). The drug distribution in a 2-D
idealised tumour geometry via TSL-mediated delivery
was examined using a transport model that ignored the
effect of convection (Zhang et al. 2009). Although a
bioheat transfer model and macroscopic transport
model were integrated in a pioneer study to simulate
TSL drug delivery under different heating schedules
(Gasselhuber et al. 2012b), existing spatially resolved
drug transport models do not include HIFU acoustics
and temperature-dependent tumour and drug
properties.
The aim of the present study is to develop a multi-
physics model for TSL-mediated drug delivery com-
bined with HIFU heating. This requires integration and
coupling of models for HIFU acoustic ﬁeld, tissue and
blood temperature, interstitial ﬂuid ﬂow, TSL and drug
transport/reaction and tumour drug uptake. The inte-
grated model has been applied to real tumour geome-
try reconstructed from patient-speciﬁc images.
Heat-induced variations in transport properties of the
drug and tumour are considered, which are temporally
and spatially dependent. Anticancer efﬁcacy is evaluated
based on the percentage of survival tumour cells by
solving the pharmacodynamics equation using the pre-
dicted intracellular drug concentration.
RESULTS
A total dose of 50 mg/m2 (Gabizon et al. 1994) TSL
doxorubicin is intravenously administrated (Gasselhu-
ber et al. 2012b) at the beginning of the treatment for a
70 kg patient, with HIFU heating being applied simul-
taneously (Liu and Xu 2015) over a period of 60 min
(Gru¨ll and Langereis 2012). The two focus regions are
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heated sequentially during the treatment, and sonica-
tion duration for each region is 1.0 s.
Interstitial ﬂuid ﬂow
Drug transport and accumulation strongly depend on
the interstitial ﬂuid ﬁeld in the tumour and surrounding
normal tissue. This is because drug migration by con-
vection is determined by the interstitial ﬂuid velocity
(IFV), while pressure gradient across the vessel wall
directly inﬂuences the transvascular exchange of ﬂuid
and drugs. The predicted spatial distribution of inter-
stitial ﬂuid pressure (IFP) corresponding to a vascular
pressure of 2080 Pa (Baxter and Jain 1989) is shown in
Fig. 1, where uniform IFP distributions can be found in
both the tumour and normal tissue. As higher IFP is
observed in the tumour (1534 Pa) than in the normal
tissue (40 Pa), pressure-induced convection of intersti-
tial ﬂuid mainly occurs within a thin layer at the inter-
face between the two regions, where there is a large IFP
gradient. The predicated IFP is found to be well within
the range reported in experiment studies (Raghunathan
et al. 2010).
High IFP in tumour is largely attributed to the leaky
vasculature and dysfunctional lymphatics. It has been
reported that large pores on tumour vasculature could
increase the wall hydraulic conductivity by 10-fold
compared to normal blood vessels (Baxter and Jain
1989), making ﬂuid exchange across the vessel wall
much easier. Additionally, the lack of functional lym-
phatic vessels results in less ﬂuid being drained out of
the extracellular space, causing the build-up of IFP in
the tumour.
HIFU acoustic ﬁeld
Figure 2 shows that the spatial distribution of acoustic
pressure is non-uniform, with the highest value of
1.98 MPa achieved at the focal centres. Outside the
focus regions, acoustic pressure falls sharply to nearly
zero. Figure 3 further reveals that there are several
acoustic pressure peaks along the major and minor axis
of the focus region. With the highest peak being at the
centre, acoustic pressure attenuates rapidly towards the
periphery, limiting the high power to a narrow region of
17.5 mm and 3.0 mm along the major and minor axis of
the focus region, respectively.
Temperature distribution in tissue and blood
Variations of temperature over time with 60-min HIFU
heating are represented in Fig. 4, which shows that
temperatures in blood, tumour and normal tissues share
a similar pattern in response to the heating schedule.
The maximum tumour temperature reaches the target
value of 42 C rapidly, and then maintains at this level
while the temperature controller described by Eq. 1 is
in action. This is followed by a fall in temperature when
HIFU heating terminates. The lower blood temperature
can be attributed to blood ﬂow that is efﬁcient to
remove heat from the HIFU focus regions, and this
forced convection via blood serves as the main mecha-
nism of heat transfer in the tumour and its holding
tissue. Results show that temperature falls back to the
normal body temperature of 37 C within 20 min after
the cessation of heating. Since the HIFU focus regions
for direct heating are located inside the tumour as
shown in Fig. 5, temperature in the tumour rises faster
and is higher than in the surrounding normal tissue,
whereas temperature elevation in normal tissue mainly
depends on heat transfer from the tumour, which in
turn causes heat loss hence reduction in tumour tem-
perature. However, given that heat is constantly carried
away by the circulating blood, blood temperature in the
tumour region is always lower than the tumour tem-
perature. As blood in the tumour region is directly
heated by HIFU, its spatial-averaged temperature is
higher than blood temperature in the normal tissue.
Spatial distribution of tissue temperature at 10 min
after heating is shown in Fig. 6. The highest tempera-
ture is observed in the focus regions where the tumour
is directly heated by HIFU. Temperature elevation in the
surrounding region is a consequence of heat transfer by
convection and conduction from the focus regions,
therefore, temperature in normal tissue is lower than in
the tumour. The large difference in spatial-mean tem-
perature between the tumour and normal tissues is
desirable for enhanced drug release in the tumour
region, while minimising drug availability in normal
tissues.
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Fig. 1 Interstitial ﬂuid pressure in tumour and surrounding
normal tissue
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Fig. 2 Spatial distribution of acoustic pressure during the sonication period of each focus region
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Fig. 3 Acoustic pressure variations in the focal plane along the major axis (A), and minor axis (B)
44
43
42
41
37
41
40
39
38
37
)nim(emiT)nim(emiT
0 30 60 90 120 150 180
BA
0 30 60 90 120 150 180
40
39
38M
a
x
im
u
m
 t
e
m
p
e
ra
tu
re
 (
°C
)
Tumour
Normal tissue
Blood in the entire domain
Tumour
Normal tissue
Blood in tumour
Blood in normal tissue
S
p
a
ti
a
l-
m
e
a
n
 t
e
m
p
e
ra
tu
re
 (
°C
)
Fig. 4 Variations of temperature in tumour, blood and normal tissue as a function of time for 60 min heating. A Maximum temperature.
B Spatial-mean temperature
RESEARCH ARTICLE W. Zhan et al.
46 | February 2019 | Volume 5 | Issue 1  The Author(s) 2019
Drug transport
Intravascular concentration of doxorubicin-loaded TSL
in tumour and normal tissue are compared in Fig. 7A as
a function of time. With bolus injection, intravascular
TSL concentration reaches its peak at the very begin-
ning of the treatment. It then falls continuously until it
drops to zero due to rapid clearance in the circulatory
system and enhanced release as temperature rises.
Because the tumour temperature is approximately 2–
3 higher than the normal tissue temperature during
HIFU heating, TSL doxorubicin concentration reduces
faster in the tumour than in normal tissue.
As shown in Fig. 7B, extracellular concentration of
TSL doxorubicin in tumour starts to increase as soon as
the treatment begins. This is owing to the high con-
centration gradient across the vasculature wall and
enhanced vascular permeability in response to tem-
perature rise. The concentration peaks at around 2 min
after heating, and reduces progressively to zero as a
result of enhanced drug release and reduced intravas-
cular concentration as shown in Fig. 7A. Quantitative
comparisons show that TSL doxorubicin concentration
in normal tissues is at least three orders of magnitude
less than in tumour, indicating that TSL doxorubicin
mainly accumulate in the tumour with less efﬁcient
penetration into the surrounding normal tissue. This is
more evident in Fig. 8 which shows the spatial distri-
bution of TSL doxorubicin in the extracellular space at
different time points. It is clear that the distribution of
TSL doxorubicin is highly heterogeneous in the tumour
upon HIFU heating. Tumour centre has lower concen-
tration than in periphery as time proceeds, due to the
fast doxorubicin release enhanced by HIFU heating
within and around the focus regions. As the intravas-
cular TSL doxorubicin concentration is reduced, the
corresponding extracellular concentration decreases in
the entire tumour and eventually become uniform.
The time course of released doxorubicin concentra-
tion in blood and tumour extracellular space is given in
Fig. 9. Doxorubicin is continuously released from TSL
upon heating, resulting in a rapid increase in both
intravascular and extracellular concentrations following
drug administration. This is followed by a gradual fall of
drug concentrations after reaching their peaks, owing to
the reduction in intravascular concentration of TSL
doxorubicin as time proceeds. Results also show
that variation of free (bioavailable) doxorubicin
concentration shares the same pattern with bound
doxorubicin concentration, although the latter is two
times higher in magnitude owing to the dynamic equi-
librium as described by Eq. 1-4 and Eq. 1-6 in Table 1.
Figure 10 displays the spatial distribution of
doxorubicin intratumoural concentrations and survival
fraction of tumour cells at 10 min after administration.
It is not surprising that doxorubicin intracellular accu-
mulation is most efﬁcient in tumour centre where HIFU
focus regions are located, and it decreases radially
towards tumour periphery with the lowest level at the
left and bottom corners. As a consequence, the most
effective cell killing occurs in the tumour centre, while
drug uptake is less effective at the left and bottom
corners which are the farthest from the focus regions.
This non-uniform enhancement of drug uptake
demonstrates the importance of the location of pre-
designed tumour regions.
Tumour drug uptake
Temporal proﬁles of intracellular drug concentration
and cell survival fraction are represented in Fig. 11. The
intracellular concentration rises to its peak at 1.15 h
after TSL doxorubicin administration, and then
gradually declines to zero. The treatment efﬁcacy is
evaluated in terms of dynamic cell density estimated by
the pharmacodynamics model. Results show that the
A B
Tumour
Focus region
Normal tissue
1 cm
Fig. 5 Model geometry. A MR image of a prostate tumour (in red)
and its surrounding tissue (in pule blue). B Reconstructed 2-D
geometry and locations of two focus regions outlined by dash
ellipses
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Fig. 6 Spatial distribution of tissue temperature at 10 min after
heating
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survival rate of tumour cells starts to fall immediately
after drug administration, but after 6 h cell killing rate
slows down until at 8 h when drug-induced cell killing
falls to zero and physiological degradation is overtaken
by that of cell proliferation, causing the percentage of
cell survival to increase gradually over time.
DISCUSSION
In this study, a multiphysics model is developed to
predict the temporal and spatial proﬁles of temperature,
drug concentrations and tumour cell survival for a TSL
doxorubicin delivery system combined with HIFU. This
integrated model is applied to a realistic prostate
tumour geometry reconstructed from medical images.
Our modelling results demonstrate the advantage of the
combined HIFU–TSL therapy in achieving enhanced
drug release at the targeted tumour site, while reducing
drug availability in normal tissues. Simulations of HIFU
heating reveals that when the acoustic power is focused
at a preselected region, only the targeted region would
experience sufﬁciently high temperature to trigger fast
drug release. Since temperature in the normal tissue is
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below the hyperthermia requirement, majority of the
encapsulated doxorubicin remains inside the liposomes.
While the primary purpose of HIFU heating is to trigger
drug release from TSL, transport properties of the drug
and tumour tissue also vary in response to temperature
elevation, leading to improved drug transport and
uptake during hyperthermia.
Tumour drug distribution and uptake can be highly
heterogeneous when a single-element transducer is
used, as the coverage of its focus region is very limited.
This would be a serious limitation for the treatment of
large tumours. In order to achieve a uniform hyper-
thermia temperature distribution within a tumour,
multi-element transducers have been used which can
simultaneously generate multiple focus regions, allow-
ing wider coverage of the targeted tumour. Careful
design of HIFU scanning trajectory and focus region
locations can help homogenise the temperature distri-
bution, so as to achieve enhanced drug release in the
entire tumour. Our results also show that incorporating
a temperature controller is effective at maintaining the
desired tumour temperature during HIFU heating.
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Table 1 Governing equations for drug transport under TSL-mediated delivery
Pharmacokinetics model
dClp
dt ¼ CLlpClp  krelClp (1-1)
Liposome encapsulated drug concentration in the interstitial ﬂuid (Cle)
oCle
ot þr  Clevð Þ ¼ Dlr2Cle þ Fv 1 rlð ÞClp þ Pl SV Clp  Cle
 
Pel
ePel1  FlyCle  krelCle;Pel ¼
Fv 1rlð Þ
Pl SV
(1-2)
Free doxorubicin concentration in blood plasma (Cfp)*
oCfp
ot ¼ krelClp  VTVB Fv 1 rfð ÞCfp þ Pfe SV Cfp  Cfe
 
Pef
ePef1
h i
 CLfpCfp  kaCfp  kdCbp
  (1-3)
Bound doxorubicin concentration in blood plasma (Cbp)*
oCbp
ot ¼ kaCfp  kdCbp
  VTVB Fv 1 rbð ÞCbp þ Pbe SV Cbp  Cbe
 
Peb
ePeb1
h i
 CLbpCbp (1-4)
Free doxorubicin concentration in interstitial ﬂuid (Cfe)*
oCfe
ot þr  Cfevð Þ ¼ Dfer2Cfe þ Fv 1 rfð ÞCfp þ Pfe SV Cfp  Cfe
 
Pef
ePef1  FlyCfe þ kdCbe  kaCfe þ DcVmax CiCiþki  CfeCfeþkeu
 
þ krelCle (1-5)
Bound doxorubicin concentration in interstitial ﬂuid (Cbe)*
oCbe
ot þr  Cbevð Þ ¼ Dber2Cbe þ Fv 1 rbð ÞCbp þ Pbe SV Cbp  Cbe
 
Peb
ePeb1  kdCbe þ kaCfe (1-6)
Intracellular doxorubicin concentration (Ci)
oCi
ot ¼ Vmax CfeCfeþkeu CiCiþki
 
(1-7)
*Pef and Peb are deﬁned in the same way as Pel in Eq. 1-2
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It is worth noting that TSL formulations can be
unstable at body temperature in human blood (Hossann
et al. 2010; Tagami et al. 2011, 2012). Ideal TSL should
be able to release its payload upon hyperthermia only
(Zou et al. 1993). However, this is difﬁcult to achieve
in vivo. Leaking at normal body temperature can lead to
build-up of free doxorubicin in the circulatory system
and normal tissue, increasing the risk of damage to
normal cells and systemic side effects, such as car-
diotoxicity (Cusack et al. 1993; Legha et al. 1982).
Therefore, further improvements in TSL facilitated
delivery combined with HIFU triggered release should
aim to minimise drug leakage at body temperature,
increase the release rate at the target temperature upon
hyperthermia and optimise the heating schedule (Liu
and Xu 2015). As a cost effective approach, mathemat-
ical modelling can facilitate comprehensive parametric
analyses to identify the most inﬂuential factors and
optimise their ranges, in order to provide guidance for
the design of TSL and treatment regimen.
Our mathematical model was developed to describe
the key interplays between solid tumour and HIFU–TSL
drug delivery system. Although a 2-D model is used in
this study for the sake of computational cost, the model
can be applied directly to 3-D tumour geometry. Nev-
ertheless, the present model involves a number of
assumptions. First, physical complexities including
cavitation and non-linear propagation of acoustic waves
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Fig. 11 The time course of intracellular concentration (A) and cell survival fraction (B) in the tumour under TSL-mediated delivery with
HIFU heating
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are ignored, but the effects of these complexities are
expected to be minor for the conditions examined here
(Sheu et al. 2011; Solovchuk et al. 2012). Second, the
inﬂuence of temperature elevation on tumour proper-
ties is complex, and not all variations are included in the
current model, such as change in interstitial ﬂuid vis-
cosity and temperature-dependent plasma clearance.
Third, focus regions are ideally positioned in the
tumour, without considering movement trajectory of
ultrasound transducer, vasculature distribution and
other microenvironment in tumour. Finally, there is a
lack of experimental data for direct comparison and
validation of our integrated model. Nevertheless, the
adopted models have been validated separately by other
researchers for HIFU acoustic ﬁeld (Sheu et al. 2011)
and HIFU-induced temperature variation (Staruch et al.
2011). The macroscopic transport model has been
shown to be able to provide qualitative predictions on
drug transport and accumulation in solid tumours
(Bhandari et al. 2017; Zhan and Wang 2018). Given the
complexities involved in the drug delivery process,
more rigorous validation studies are needed in the
future. Since averaged and representative values of
model parameters are used in our simulations, the
numerical results presented in this study are meant for
qualitatively analysis rather than quantitative
prediction.
CONCLUSIONS
A multiphysics model has been developed to examine
the spatial distribution and temporal variation of TSL
drug concentration, temperature upon HIFU heating and
drug uptake for a combined HIFU–TSL doxorubicin
delivery system. Our results demonstrate the capability
of the model to simulate such a complex system, and
indicate that this combined drug delivery system is able
to achieve a localised treatment with enhanced drug
delivery to tumour interior while keeping a rela-
tively low level of drug concentration in normal tissue.
The developed modelling framework can serve as a
foundation for further comprehensive studies of
TSL-mediated drug delivery with HIFU heating.
METHODS
Mathematical model
This modelling framework consists of several modules
describing the different physical and biochemical pro-
cesses involved in a HIFU–TSL drug delivery system. The
relevant governing equations are summarised in
Tables 1, 2, 3, 4 and 5 and their details are described
below.
Interstitial ﬂuid ﬂow
The bulk movement of interstitial ﬂuid in tissue extra-
cellular space and the ﬂuid exchange with systemic
blood and lymphatic systems are crucial for drug
transport in solid tumour. Given the size of a tumour is
typically 2–3 orders of magnitude larger than the inter-
capillary distance, tumour and its surrounding normal
tissue are treated as rigid porous media, with blood
capillaries being represented as a uniformly distributed
source term (Baxter and Jain 1989). Table 2 shows the
continuity and momentum equations applied to
describe the ﬂow of incompressible Newtonian inter-
stitial ﬂuid in a porous medium.
HIFU acoustic ﬁeld
Since acoustic energy radiated from a concave surface
tends to be focused near the centre of curvature, such
radiators have been used to produce localised heating
in clinical applications. The effect of non-linear acous-
tic wave propagation on the heating of biological tis-
sues by HIFU can be ignored if the applied focal
intensity is within the range of 100–1000 W/cm2 and
the peak negative pressure in the range of 1–4 MPa
(Sheu et al. 2011; Solovchuk et al. 2012). The acoustic
ﬁeld under the aforementioned conditions can be
described by the fundamental equations (O’Neil 1949)
given in Table 3.
Bioheat transfer
Both the tissue and blood are heated by absorbing the
acoustic energy induced by HIFU, and heat can be
transferred between these two compartments if there is
a temperature difference. Because of continuous blood
circulation, the heated blood at temperature Tb will ﬂow
out of the heating region while blood at normal tem-
perature Tn ﬂows in. The corresponding energy con-
servation equations are summarised in Table 4.
Table 2 Governing equations for interstitial ﬂuid ﬂow
Continuity equation
r  v ¼ Fv  Fly (2-1)
Fv ¼ Kv SV pv  pi  r pv  pið Þ½ ; Fly ¼ Kly SlyV pi  ply
 
(2-2)
Momentum equation
o qvð Þ
ot þr  qvvð Þ ¼ rpi þr  s lj v (2-3)
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Drug transport
Systemic administration is the main delivery method in
chemotherapy. Following systemic administration, TSL
and chemotherapy drugs (doxorubicin is used here)
undergo a series of steps as illustrated in Fig. 12. Brieﬂy,
the tumour region consists of three compartments:
systemic blood, extracellular space and tumour cells.
Within each compartment, letters F, B and L represent
free (bioavailable), bound and liposomal doxorubicin,
respectively.
Drug transport is determined by drug properties and
the in vivo environment after administration. The
dynamic process of TSL drug delivery includes triggered
drug release from liposomes, association/disassociation
of free drugs with proteins, plasma clearance, drug
circulation within bloodstream, and exchanges among
the circulatory system, extracellular space and tumour
cells. The full set of mathematical descriptions is given
in Table 1.
Pharmacodynamics model
Dynamic tumour cell density is determined by drug
cytotoxicity, cell proliferation and physiologic degrada-
tion, as described in Table 5. In this study, cell prolif-
eration and physiologic degradation are assumed to
have reached equilibrium at the start of each treatment.
Model geometry
The geometry of a prostate tumour is reconstructed
from magnetic resonance (MR) images acquired from a
patient using a 3.0-Tesla MR scanner (DISCOVERY
MR750, GE, Schenectady, New York, USA). Multi-slice
anatomical images of the prostate were acquired in
three orthogonal planes with echo-planer (EP)
sequence, with each image comprising 256 by 256
pixels. In order to build a 2-D model of the tumour and
its holding tissue, a representative transverse MR image
is selected to cover the maximum tumour dimension, as
shown in Fig. 5A. The transverse image is processed
using image analysis software MIMICS (Materialise HQ,
Leuven, Belgium), and the tumour is segmented from its
surrounding normal tissue based on the local signal
intensity.
The tumour shown in Fig. 5B is located at the corner
of the normal tissue with a dimension of 47 mm
(maximum width) by 38 mm (maximum depth) in the
Table 3 Acoustic model for high intensity focused ultrasound
x
Q
C
r
s
R
Q
1
R1
O
S A
ab
h
α
α
θ
θ1
Acoustic intensity (Ia)
Ia ¼ p2a=2qma (3-1)
Acoustic pressure (pa)
pa ¼ ikacqmaW; kac ¼ 2p=k (3-2)
Acoustic velocity potential (W)
W R; hð Þ ¼ u2p r
2p
0
r
b
0
s1eikacsR1dR1db;
u ¼ u0eixt ;
s ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃR2  2Rr1sinhcosbþ zR21
p
;
z ¼ 1 2hR cos h=b2; r1 ¼ R1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 R21=4A2
 q
(3-3)
Table 4 Bioheat transfer
model
Bioheat transfer in tumour and normal tissue
qtct
oTt
ot ¼ ktr2Tt  qbcbwb Tt  Tbð Þ þ 2atIa (4-1)
Bioheat transfer in blood
qbcb
oTb
ot ¼ kbr2Tb þ qbcbwb Tt  Tbð Þ  qbcbwb Tb  Tnð Þ þ 2abIa (4-2)
Table 5 Pharmacodynamics model
Pharmacodynamics model
dDc
dt ¼  fmaxCiEC50þCi Dc þ kpDc  kgD2c (5-1)
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2-D cross-sectional model. Two focus regions are chosen
in order to achieve good coverage of the tumour
(Mougenot et al. 2009). Both regions are elliptical with
major and minor axis radii of 8.7 mm and 1.5 mm,
respectively. ANSYS ICEM CFD (ANSYS Inc., Canonsburg,
USA) is used to generate the computational mesh, which
consists of 64,966 triangular elements in total. This is
obtained based on mesh independence tests which
show that differences in predicted acoustic pressure,
temperature and drug concentration between the
adopted mesh and a 10-times ﬁner mesh are less than
1%.
Model parameters
Parameters describing the basic physical and transport
properties of free, bound and TSL doxorubicin, as well
as tumour and normal tissue are summarised in
Tables 6, 7, 8 and 9. Justiﬁcations for the choices of
these parameters have been reported in our previous
publications (Zhan et al. 2014a, b). Since temperature
elevation in response to HIFU heating may inﬂuence
several properties used in the drug transport model,
temperature dependence of the following transport
properties is considered: vascular permeability, diffu-
sivity, transmembrane rate, blood perfusion rate and
drug release rate from TSL.
HIFU transducer
The acoustic source is a single-element, spherically
focused transducer, and the geometric parameters are
listed in Table 10. The local acoustic intensity and peak
negative pressure are set as 120 W/cm2 and 1.98 MPa,
respectively.
Temperature controller
With TSL drug delivery systems, it is desirable to keep
the tumour temperature within a narrow hyperthermia
range which should not exceed 43 C to avoid irre-
versible tissue damage (Curiel et al. 2004). The phase
transition temperature of TSL strongly depends on its
formulation, and a typical value for TSL doxorubicin is
42 C based on experimental studies (Tagami et al.
2012). In order to achieve the target temperature range,
a feedback temperature controller is incorporated,
which is designed to adjust the applied ultrasound
power according to the maximum temperature in the
heated region (Tmax). The transducer power is adjusted
according to the controller parameter P(t), which is
determined by
P tð Þ ¼ kcp Ttarget  Tmax tð Þ
 þ kci
X
Ttarget  Tmax tð Þ
 
;
ð1Þ
where kcp and kci are proportional-integral (PI) control
parameters, which are set as 5.0 and 6.0 9 10-3
respectively, based on values in the literature (Staruch
et al. 2011) and our previous studies.
Vascular permeability
Vascular permeability measures the capacity of a blood
vessel (often capillary in tumour) wall to allow for the
ﬂow of substances in and out of the vasculature. The
structure of vessel wall and the molecular size of the
transported substance are key determinants of per-
meability (Yuan et al. 1995). The logarithmic values of
free doxorubicin permeability were found to be pro-
portional to temperature (Dalmark and Storm 1981) as
shown in Fig. 13A. The permeability of bound
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doxorubicin is assumed to follow the same relation.
Compared to baseline values at 34 C, extracellular
concentrations of TSL encapsulated doxorubicin
increased by 38-fold and 76-fold upon heating to 42 C
and 45 C, respectively (Gaber et al. 1996), based on
which the relationship between fold increase in TSL
permeability and temperature can be obtained as
shown in Fig. 13B.
Diffusivity
According to the Einstein–Stokes equation (Jain 1987b),
the fold increase in diffusivity as a function of thermo-
dynamic temperature is
D1
D2
¼ T

1l2
T2l1
; ð2Þ
where D strands for diffusivity, T* is the thermodynamic
temperature and l is the dynamic viscosity of solvent.
Subscripts 1 and 2 correspond to conditions 1 and 2,
respectively. Owing to the lack of relevant data, dynamic
viscosity values in Eq. 2 are assumed to be those of
water (Keenan and Keyes 1936), whose dependence on
temperature is given in Fig. 13C.
Transmembrane rate
The transmembrane parameter is determined by
curve ﬁtting to data obtained from in vitro experi-
ments (El-Kareh and Secomb 2000; Kerr et al. 1986).
It has been suggested that increased cellular uptake of
doxorubicin with heating can lead to improved out-
come when the drug is administrated simultaneously
with hyperthermia (El-Kareh and Secomb 2000).
Based on data in the literature (Nagaoka et al. 1986),
there is a 2.2-fold increase at 42 C. Here, the fold
increase (ktv) at temperature T is obtained by linear
interpolation as
ktv ¼ 0:24T  7:88: ð3Þ
Table 6 Biophysical parameters for tumour and normal tissues
Parameter Deﬁnition Unit Tumour
tissue
Normal
tissue
References
S/V Surface area of blood vessels
per unit tissue volume
m-1 2.0 9 104 7.0 9 103 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
Kv Hydraulic conductivity of the
micro-vascular wall
m/(Pas) 2.10 9 10-11 2.70 9 10-12 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
q Density of interstitial ﬂuid kg/m3 1000 1000 (Goh et al. 2001)
l Dynamic viscosity of
interstitial ﬂuid
kg/(ms) 7.8 9 10-4 7.8 9 10-4 (Goh et al. 2001)
1/j Permeability of the interstitial
space
m-2 4.56 9 1016 2.21 9 1017 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
pv Vascular ﬂuid pressure Pa 2080 2080 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
pv Osmotic pressure of the
plasma
Pa 2666 2666 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
pi Osmotic pressure of
interstitial ﬂuid
Pa 2000 1333 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
rT Average osmotic reﬂection
coefﬁcient for plasma
proteins
0.82 0.91 (Baxter and Jain 1989, 1990, 1991;
Goh et al. 2001)
KlySly/V Hydraulic conductivity of the
lymphatic wall times
surface area of lymphatic
vessels per unit volume of
tumour tissue
(Pas)-1 0 4.17 9 10-7 (Goh et al. 2001)
ply Intra-lymphatic pressure Pa 0 0 (Goh et al. 2001)
Dc Cell density 10
5cell/m3 1 9 1010 – (Eikenberry 2009)
VT Total tumour volume m
3 5 9 10-5 3 9 10-4 (El-Kareh and Secomb 2000)
VB Total blood volume in body m
3 5 9 10-2 5 9 10-2 (El-Kareh and Secomb 2000)
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Table 7 Transport parameters for doxorubicin
Parameter Deﬁnition Unit Free
doxorubicin
Bound
doxorubicin
References
Ptumour Permeability of
vasculature wall in
tumour
m/s 3.00 9 10-6 7.80 9 10-9 (Goh et al. 2001; Wu et al. 1993b)
Pnormal Permeability of
vasculature wall in
normal tissue
m/s 3.75 9 10-7 2.50 9 10-9 (Goh et al. 2001; Wu et al. 1993b)
Dtumour Diffusion coefﬁcient in
interstitial ﬂuid of
tumour
m2/s 3.40 9 10-10 8.89 9 10-12 (Goh et al. 2001; Granath and Kvist 1967; Jain
1987b; Nugent and Jain 1984; Saltzman and
Radomsky 1991; Swabb et al. 1974)
Dnormal Diffusion coefﬁcient in
interstitial ﬂuid of
normal tissue
m2/s 1.58 9 10-10 4.17 9 10-12 (Goh et al. 2001; Granath and Kvist 1967; Jain
1987b; Nugent and Jain 1984; Saltzman and
Radomsky 1991; Swabb et al. 1974)
rd Osmotic reﬂection
coefﬁcient
0.15 0.82 (Goh et al. 2001; Wolf et al. 1987)
ka Doxorubicin-protein
binding rate
s-1 0.833 – (Eikenberry 2009)
kd Doxorubicin-protein
dissociation rate
s-1 – 0.278 (Eikenberry 2009)
u Tumour fraction
extracellular space
0.4 (Eikenberry 2009)
Vmax Rate of
transmembrane
transport
kg/105cells 4.67 9 10-15 – (Eikenberry 2009; Kerr et al. 1986)
ke Michaelis constant for
transmembrane
transport
kg/m3 2.19 9 10-4 – (Eikenberry 2009; El-Kareh and Secomb 2000; Kerr
et al. 1986)
ki Michaelis constant for
transmembrane
transport
kg/105
cells
1.37 9 10-12 – (Eikenberry 2009; El-Kareh and Secomb 2000; Kerr
et al. 1986)
fmax Cell-kill rate constant s
-1 1.67 9 10-5 – (Eliaz et al. 2004)
EC50 Drug concentration
producing 50% of
fmax
kg/105
cells
5.00 9 10-13 – (Eliaz et al. 2004)
kp Cell proliferation rate s
-1 3.00 9 10-6 – (Liu et al. 2013)
kg Cell physiologic
degradation rate
s-1 3.00 9 10-16 – (Liu et al. 2013)
CLtumour Plasma clearance in
tumour
s-1 2.43 9 10-3 0 (Benet and Zia-Amirhosseini 1995; Robert et al.
1982; Rodvold et al. 1988; Solovchuk et al. 2012)
CLnormal Plasma clearance in
normal tissue
s-1 2.43 9 10-3 0 (Benet and Zia-Amirhosseini 1995; Robert et al.
1982; Rodvold et al. 1988; Solovchuk et al. 2012)
Table 8 Transport parameters for liposome
Parameter Deﬁnition Unit Tumour Normal tissue References
Pl Liposome permeability of vasculature wall m/s 3.42 9 10
-9 8.50 9 10-10 (Wu et al. 1993a; Yuan et al. 1994)
Dl Liposome diffusion coefﬁcient m
2/s 9.00 9 10-12 5.80 9 10-12 (Wu et al. 1993a; Yuan et al. 1995)
rl Reﬂection coefﬁcient for liposome – 0.95 1.0 (Zhan et al. 2014a)
CLlp Plasma clearance in tumour s
-1 2.23 9 10-4 2.23 9 10-4 (Gabizon et al. 1994)
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Table 9 Acoustic and thermal properties
Parameter Deﬁnition Unit Value References
Blood Tumour Normal tissue
va Ultrasound speed m/s 1540 1550 1550 (Sheu et al. 2011)
q Density kg/m3 1060 1000 1055 (Sheu et al. 2011)
c Speciﬁc heat J/(kgK) 3770 3800 3600 (Sheu et al. 2011)
k Thermal conductivity W/(mK) 0.53 0.552 0.512 (Sheu et al. 2011)
a Absorption coefﬁcient – 1.5 fac
* 9 fac
* 9 fac
* (Sheu et al. 2011)
wb0 Blood perfusion rate at 37 C s-1 – 0.002 0.018 (Vaupel et al. 1989)
R Universal gas constant J/(molK) – 8.314 8.314 (Schutt and Haemmerich 2008)
DE Activation energy J/mol – 6.67 9 105 6.67 9 105 (Schutt and Haemmerich 2008)
Af Frequency factor s
-1 – 1.98 9 10106 1.98 9 10106 (Schutt and Haemmerich 2008)
*fac represents ultrasound frequency
Table 10 HIFU transducer parameters
Inside diameter (mm) Outside diameter (mm) Focal length (mm) Frequency (MHz)
20.0 70.0 62.64 1.10
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Fig. 13 Derivation of transport parameters from experimental data. A Permeability of free doxorubicin (Dalmark and Storm 1981).
B Fold increase in permeability of TSL-loaded doxorubicin (Gaber et al. 1996). C Water dynamic viscosity (Keenan and Keyes 1936).
D Drug release rate (Tagami et al. 2012). Experimental data are represented by black dots, and ﬁtting curves are shown in red with the
corresponding equations
RESEARCH ARTICLE W. Zhan et al.
56 | February 2019 | Volume 5 | Issue 1  The Author(s) 2019
Blood perfusion rate
Blood perfusion rate (w) varies with temperature
(Schutt and Haemmerich 2008) according to the fol-
lowing relation
w ¼ w0exp 
Zt
0
Afe
DE=RT tð Þds
0
@
1
A; ð4Þ
where w0 represents the perfusion rate at 37 C, and
the thermodynamic temperature T* is a function of time
t. R is the universal gas constant, and Af and DE repre-
sent the frequency factor and the activation energy,
respectively.
Drug release rate from TSL
TSL is designed to release its payload rapidly upon
heating (Zou et al. 1993). The exact release rate varies
according to the composition of liposome, its prepara-
tion procedure and heating temperature (Tagami et al.
2011). The relation between percentage release and
exposure time is found to follow the ﬁrst-order kinetics
expressed as (Afadzi et al. 2010)
%R tð Þ ¼ Rc 1 ekrelt
 
; ð5Þ
where %R(t) is the percentage of drug released at
exposure time t, Rc is the total percentage of drug
released at a given heating temperature. This equation
is used to ﬁt experimental data (Tagami et al. 2012) and
an example for 37 C is given in Fig. 13D. Drug release
rates at different temperatures in the range of 37–42 C
are summarised in Table 11.
Note that the TSL formulation used in Tagami et al.’s
study (2012) still allows some drugs to be slowly
released at 37 C, although release at 42 C is much
faster. Linear interpolation is performed to obtain
release rate at temperatures between the available
temperature points, and the release rate is assumed to
be constant if temperature exceeds 42 C.
Numerical methods
The mathematical models are implemented into a ﬁnite-
volume method based computational ﬂuid dynamics
code, ANSYS FLUENT (ANSYS Inc., Canonsburg, USA). The
user deﬁned scalar function is used to code bioheat
transfer model, pharmacokinetics, mass transfer equa-
tions for drug transport and pharmacodynamics model.
The partial differential equations are spatially discretised
by using the 2nd order UPWIND scheme, and the
SIMPLEC algorithm is employed for pressure–velocity
coupling. The convergence is controlled by setting
residual tolerances of the momentum equation, mass
transfer equations and bioheat transfer equations to be
1 9 10-5, 1 9 10-8 and 1 9 10-10, respectively. Inter-
stitial ﬂuid equations are solved ﬁrst to obtain a steady-
state solution for the entire computational domain. The
obtained pressure and velocity ﬁelds are adopted as ini-
tial values for the simulation of bioheat transfer, drug
transport, drug uptake and cell density simultaneously.
The 2nd order implicit backward Euler scheme is
employed for temporal discretization. A ﬁxed time-step
size of 0.1 s is chosen after time-step sensitivity tests.
Boundary conditions
For a single chemotherapy treatment, the simulated
time window is much shorter than that required for
tumour growth. Consequently, all boundaries of the
tumour and normal tissue are assumed to be ﬁxed. The
interface between the tumour and normal tissue is
treated as an internal boundary where all variables are
continuous. At the outer surface of normal tissue, a
relative pressure of 0 Pa and temperature of 37 C are
speciﬁed, together with zero ﬂux of drugs.
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Table 11 Release rates at various temperatures
T (oC) 37.0 38.0 39.0 40.0 41.0 42.0
krel (s
-1) 4.17 9 10-3 5.45 9 10-3 1.49 9 10-2 2.82 9 10-2 4.25 9 10-2 5.41 9 10-2
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